DIAN-TU Primary Prevention Trial for Dominantly Inherited Alzheimer’s Disease
Official title: DIAN-TU Primary Prevention Trial
Funded at Washington University · NIH-11579121 · Data updated 2026-11-12
A nationwide clinical trial tests whether early treatment can delay or prevent cognitive decline in people who carry genetic risk for a form of Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 15, 2018 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $17,276 |
| NIH project number | 3R01AG059798-06S3 |
| Project ID | NIH-11579121 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are asymptomatic individuals with dominantly inherited Alzheimer’s disease mutations, ages (as specified by study criteria) and minimal to no brain amyloid at entry.
✕Less likely to help
Individuals without the DIAD mutation or those with advanced amyloid accumulation at entry may see limited or no benefit.
What this research studies
This trial platform focuses on people who are genetically destined to develop dominantly inherited Alzheimer’s disease but are still asymptomatic. It plans a multi-stage, blinded, placebo-controlled approach across 160 participants who are 11 to 25 years from expected symptom onset, starting with remternetug. Conducted at 40 sites in 16 countries, the study aims to see if removing amyloid plaques early can modify the disease course before symptoms appear. The project builds on an established DIAN-TU infrastructure to run rigorous interventional trials in a highly specialized population.
Why it matters
Potential benefit: If successful, the trial could dramatically slow or prevent dementia in people with this genetic form of Alzheimer’s disease and inform strategies for broader prevention.
How similar studies have gone: Previous amyloid-targeting trials in similar settings have shown cognitive benefits when started early, supporting the rationale for this prevention-focused approach.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Mcdade, Eric Martin — Washington University
- Study coordinator: Mcdade, Eric Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.